Tirzepatide
A dual GIP and GLP-1 receptor agonist used in FDA-approved products for type 2 diabetes and chronic weight management.
Also referenced as: Mounjaro, Zepbound
This peptide maps to at least one regulated medical product or label context in the United States.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
Mounjaro, Zepbound
FDA label signal · 233 trials · 1809 PubMed results
What tirzepatide is
Tirzepatide is a dual agonist that targets both GIP and GLP-1 pathways. It is marketed in FDA-approved products including Mounjaro and Zepbound, with the indication depending on the specific label.
Why it stands out
Tirzepatide matters because it moved beyond the single-pathway GLP-1 story and helped establish the market for dual- and triple-agonist obesity therapeutics.
Regulatory context
FDA announced the approval of Zepbound for chronic weight management on November 8, 2023:
FDA has also published safety and enforcement material addressing unapproved versions of tirzepatide sold outside approved channels:
Why that matters for researchers
Tirzepatide is a good example of how fast the public conversation can outrun the regulatory one. The ingredient may be familiar, but product category still matters:
- FDA-approved branded product
- compounded product
- research-market listing
Those carry different expectations for quality control, labeling, and oversight.
Where tirzepatide fits in the landscape
If semaglutide helped normalize GLP-1-based weight management, tirzepatide helped raise the performance ceiling and opened the door for the newer triple-agonist pipeline that includes compounds like retatrutide.